FGFR2 aberrations are estimated to be present in approximately 15–20% of cases of intrahepatic cholangiocarcinoma (iCCA), which has led to the development and testing of drugs that target FGFR2 [20,21]. This evidence concerns the gene FGFR2 and infantile convulsions and choreoathetosis.